Lifesci Capital Has Negative Estimate for VRDN Q3 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Stock analysts at Lifesci Capital reduced their Q3 2025 earnings per share (EPS) estimates for Viridian Therapeutics in a report issued on Wednesday, August 6th. Lifesci Capital analyst R. Katkhuda now expects that the company will earn ($1.03) per share for the quarter, down from their previous forecast of ($0.90). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Lifesci Capital also issued estimates for Viridian Therapeutics’ Q4 2025 earnings at ($1.06) EPS and FY2025 earnings at ($3.96) EPS.

Several other research firms have also recently commented on VRDN. HC Wainwright restated a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Royal Bank Of Canada reduced their price objective on Viridian Therapeutics from $45.00 to $41.00 and set an “outperform” rating for the company in a research note on Thursday. Oppenheimer raised their price objective on Viridian Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Thursday. Wells Fargo & Company decreased their target price on Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a research report on Thursday. Finally, JMP Securities reduced their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $37.00.

Viridian Therapeutics Stock Down 0.7%

Shares of Viridian Therapeutics stock opened at $16.41 on Monday. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04. The business’s 50 day simple moving average is $15.95 and its 200-day simple moving average is $15.17. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -4.28 and a beta of 0.42. Viridian Therapeutics has a twelve month low of $9.90 and a twelve month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, meeting analysts’ consensus estimates of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. During the same quarter in the prior year, the business posted ($0.81) earnings per share. Viridian Therapeutics’s revenue for the quarter was up 4.2% on a year-over-year basis.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors have recently made changes to their positions in VRDN. Amalgamated Bank increased its position in shares of Viridian Therapeutics by 49.7% during the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock valued at $34,000 after purchasing an additional 840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock worth $669,000 after buying an additional 876 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Viridian Therapeutics by 2.9% during the 1st quarter. SG Americas Securities LLC now owns 31,972 shares of the company’s stock worth $431,000 after buying an additional 887 shares in the last quarter. Voya Investment Management LLC lifted its holdings in Viridian Therapeutics by 5.1% during the 4th quarter. Voya Investment Management LLC now owns 21,397 shares of the company’s stock worth $410,000 after buying an additional 1,038 shares in the last quarter. Finally, Tudor Investment Corp ET AL lifted its holdings in Viridian Therapeutics by 3.0% during the 4th quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company’s stock worth $735,000 after buying an additional 1,106 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.